company background image
PPGN

PolyPeptide Group SWX:PPGN Stock Report

Last Price

CHF72.45

Market Cap

CHF2.4b

7D

7.8%

1Y

-7.5%

Updated

23 May, 2022

Data

Company Financials +
PPGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance1/6
Financial Health5/6
Dividends0/6

PPGN Stock Overview

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide.

PolyPeptide Group Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for PolyPeptide Group
Historical stock prices
Current Share PriceCHF72.45
52 Week HighCHF147.40
52 Week LowCHF60.55
Beta0
1 Month Change-18.32%
3 Month Change-6.88%
1 Year Change-7.53%
3 Year Changen/a
5 Year Changen/a
Change since IPO-7.35%

Recent News & Updates

Mar 23
Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Despite posting some strong earnings, the market for PolyPeptide Group AG's ( VTX:PPGN ) stock hasn't moved much. Our...

Shareholder Returns

PPGNCH Life SciencesCH Market
7D7.8%0.2%-2.8%
1Y-7.5%-8.7%-2.4%

Return vs Industry: PPGN exceeded the Swiss Life Sciences industry which returned -8.7% over the past year.

Return vs Market: PPGN underperformed the Swiss Market which returned -2.4% over the past year.

Price Volatility

Is PPGN's price volatile compared to industry and market?
PPGN volatility
PPGN Average Weekly Movement8.3%
Life Sciences Industry Average Movement7.1%
Market Average Movement5.0%
10% most volatile stocks in CH Market9.0%
10% least volatile stocks in CH Market2.5%

Stable Share Price: PPGN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PPGN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
19521,101Raymond De Vrehttps://www.polypeptide.com

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies.

PolyPeptide Group Fundamentals Summary

How do PolyPeptide Group's earnings and revenue compare to its market cap?
PPGN fundamental statistics
Market Cap€2.32b
Earnings (TTM)€47.26m
Revenue (TTM)€283.33m

49.2x

P/E Ratio

8.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PPGN income statement (TTM)
Revenue€283.33m
Cost of Revenue€182.43m
Gross Profit€100.91m
Other Expenses€53.65m
Earnings€47.26m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.43
Gross Margin35.61%
Net Profit Margin16.68%
Debt/Equity Ratio2.7%

How did PPGN perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

20%

Payout Ratio

Valuation

Is PolyPeptide Group undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


49.18x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: PPGN (CHF72.45) is trading above our estimate of fair value (CHF25.95)

Significantly Below Fair Value: PPGN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PPGN is poor value based on its PE Ratio (49.2x) compared to the Swiss Life Sciences industry average (46.4x).

PE vs Market: PPGN is poor value based on its PE Ratio (49.2x) compared to the Swiss market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: PPGN is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: PPGN is overvalued based on its PB Ratio (5.5x) compared to the CH Life Sciences industry average (4.2x).


Future Growth

How is PolyPeptide Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PPGN's forecast earnings growth (15.3% per year) is above the savings rate (-0.3%).

Earnings vs Market: PPGN's earnings (15.3% per year) are forecast to grow faster than the Swiss market (6% per year).

High Growth Earnings: PPGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: PPGN's revenue (12.4% per year) is forecast to grow faster than the Swiss market (4.3% per year).

High Growth Revenue: PPGN's revenue (12.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PPGN's Return on Equity is forecast to be low in 3 years time (14.8%).


Past Performance

How has PolyPeptide Group performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


50.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: PPGN has a high level of non-cash earnings.

Growing Profit Margin: PPGN's current net profit margins (16.7%) are higher than last year (14%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PPGN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare PPGN's past year earnings growth to its 5-year average.

Earnings vs Industry: PPGN earnings growth over the past year (50.8%) underperformed the Life Sciences industry 50.8%.


Return on Equity

High ROE: PPGN's Return on Equity (11.2%) is considered low.


Financial Health

How is PolyPeptide Group's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PPGN's short term assets (€331.6M) exceed its short term liabilities (€104.0M).

Long Term Liabilities: PPGN's short term assets (€331.6M) exceed its long term liabilities (€69.9M).


Debt to Equity History and Analysis

Debt Level: PPGN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PPGN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: PPGN's debt is well covered by operating cash flow (501%).

Interest Coverage: PPGN's interest payments on its debt are well covered by EBIT (22.8x coverage).


Balance Sheet


Dividend

What is PolyPeptide Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.41%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: PPGN's dividend (0.41%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.88%).

High Dividend: PPGN's dividend (0.41%) is low compared to the top 25% of dividend payers in the Swiss market (3.91%).


Stability and Growth of Payments

Stable Dividend: PPGN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.

Growing Dividend: PPGN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: PPGN is not paying a notable dividend for the Swiss market.


Cash Payout to Shareholders

Cash Flow Coverage: PPGN is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Raymond De Vre (53 yo)

1.08yrs

Tenure

Dr. Raymond De Vré, Ph D served as Senior Vice President and Head Biologics at Dr. Reddy’s Laboratories Ltd. since June 01, 2018 until 2021, a division that focuses on the development of biosimilar molecul...


Leadership Team

Experienced Management: PPGN's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: PPGN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PolyPeptide Group AG's employee growth, exchange listings and data sources


Key Information

  • Name: PolyPeptide Group AG
  • Ticker: PPGN
  • Exchange: SWX
  • Founded: 1952
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CHF2.398b
  • Shares outstanding: 33.10m
  • Website: https://www.polypeptide.com

Number of Employees


Location

  • PolyPeptide Group AG
  • Dammstrasse 19
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.